Clinicopathological Features and Immunohistochemical Comparison of Primary Peritoneal and Primary Ovarian Serous Papillary Carcinoma
-
摘要:
目的 分析比较原发于腹膜和卵巢的浆液性乳头状腺癌的临床病理特征及免疫组化特点。 方法 选取北京协和医院手术切除的10例符合原发性腹膜浆液性乳头状腺癌(primary peritoneal serous papillary carcinoma, PPSPC)定义(即病变以腹膜或网膜为主, 双侧卵巢结构正常, 或病变仅累及卵巢表面上皮)及20例与之临床分期配对的原发性卵巢浆液性乳头状腺癌(ovarian serous papillary cancer, OSPC)的病例标本, 分析PPSPC和OSPC临床病理学特点, 用免疫组织化学染色法观察雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人表皮生长因子受体2(human epidermalgrowth factor receptor2, HER2)及P53蛋白的表达; 采用荧光原位杂交(fluorescence in situ hybridization, FISH)检测两组标本的HER2基因状态。 结果 PPSPC患者平均发病年龄较OSPC患者大8.3岁, 两组比较差异具有统计学意义(P=0.045)。PPSPC患者中60%为低分化浆液性癌, 而OSPC患者中仅20%为低分化浆液性癌, 两组比较差异具有统计学意义(P=0.045)。免疫组化结果显示, ER和PR在PPSPC组中的表达(分别为60%和10%)明显低于OSPC组(分别为95%和50%)(P=0.031和P=0.032)。P53蛋白在两组中的表达与ER和PR类似, 40% PPSPC病例P53呈阳性表达, 85% OSPC病例P53呈阳性表达, 两组比较差异具有统计学意义(P=0.045)。PPSPC组中仅1例(10%, 1/10)出现轻度不连续细胞膜着色(即1+), 而OSPC组则有3例(15%, 3/20)出现HER2(1+); PPSPC及OSPC组均无HER2过表达病例。此外, 在PPSPC与OSPC组均未发现HER2基因扩增或基因拷贝数高度增加。 结论 PPSPC与OSPC尽管在组织病理学、临床特点及分子生物学特征上有相似之处, 但前者更常见于老年女性, 肿瘤分化差, 具有较强的侵袭性, ER和/或PR低表达, P53阳性表达也低于后者, 临床结局不良。 -
关键词:
- 腹膜浆液性乳头状腺癌 /
- 卵巢浆液性乳头状腺癌 /
- 临床病理 /
- 免疫组化 /
- 荧光原位杂交
Abstract:Objective To explore the clinicopathological features of primary peritoneal and primary ovarian serous papillary carcinoma in Chinese patients. Methods The clinical specimens were obtained from 10 patients who were confirmed to be with primary peritoneal serous papillary carcinoma (PPSPC) and from 20 otherwise-matched patients with ovarian serous papillary cancer (OSPC). The clinicopathological features of these PPSPC and OSPC cases were observed. The levels of estrogen receptors (ER), progesterone receptors (PR), human epidermalgrowth factor receptor 2 (HER2)/neu and P53 protein were detected using immuno-histochemical techniques. The status of HER2 gene was evaluated by fluorescence in situ hybridization (FISH) using PathVysionTM kit. Results The mean onset age was 8.3 years older among PPSPC patients than in OSPC patients (P=0.045). The proportion of poorly differentiated serous cancer was 60% among the PPSPC patients and 20% among the OSPC patients (P=0.045). Positive immunostaining for ER and PR was significantly less in PPSPC (60% and 10%, respectively) than OSPC (95% and 50%; P=0.031 and P=0.032, respectively). Positive expression of P53 was found in 40% of the PPSPC patients and 85% of the OSPC patients (P=0.045). HER2/neu was faint/barely perceptible membrane staining (1 +) in 10% of the PPSPC patients versus 15% of the OSPC patients. In addition, HER2 amplification was not found in either group. Conclusions PPSPC and OSPC share some clinicohistological features; however, compared with OSPC, PPSPC is more common in older women, with relatively poorer differentiation, stronger potential of invasion, lower ER/PR expression, lower P53 protein expression, and poorer outcomes. -
表 1 4种抗体实验室来源与实验条件
表 2 原发性腹膜浆液性乳头状腺癌与卵巢浆液性乳头状腺癌临床病理特点(n)
-
[1] Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary:case report[J]. Am J Obstet Gynecol, 1959, 77:197-200. doi: 10.1016/0002-9378(59)90287-X [2] Stenchever M, Embryology[M]//Droegemuller W, Herbst AL, Mishell Jr DR, et al. Comprehensive gynecology. St. Louis: CV Mosby, 1988: 8-11. [3] Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma:a case-control retrospective comparison to papillary adenocarcinoma of the ovary[J]. Gynecol Oncol, 1993, 50:347-351. doi: 10.1006/gyno.1993.1223 [4] Zhang C, Li XP, Cui H, et al. Advanced primary peritoneal carcinoma:clinicopathological and prognostic factor analyses[J]. J Zhejiang Univ Sci B, 2008, 9:435-440. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408695/ [5] Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface:matched-case comparison with papillary serous ovarian carcinoma[J]. Gynecol Oncol, 1993, 51:171-174. doi: 10.1006/gyno.1993.1267 [6] Shen DH, Khoo US, Xue WC, et al. Primary peritoneal malignant mixed mullerian tumors. A clinicopathologic, immunohistochemical and genetic study[J]. Cancer, 2001, 91:1052-1060. doi: 10.1002/1097-0142(20010301)91:5<1052::AID-CNCR1097>3.0.CO;2-A [7] Halperin R, Zehavi S, Hadas E, et al. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma[J]. Int J Gynecol Pathol, 2001, 20:341-345. doi: 10.1097/00004347-200110000-00005 [8] Schorge JO, Muto MG, Lee SJ, et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis[J]. Cancer Res, 2000, 60:1361-1364. http://www.ncbi.nlm.nih.gov/pubmed/10728699 [9] International Federation of Gynecology and Obstetrics. Staging announcement:FIGO Cancer Committee[J]. Gynecol Oncol, 1986, 25:383-385. doi: 10.1016/0090-8258(86)90092-2 [10] Hammock L, Lewis M, Phillips C, et al. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization[J]. Hum Pathol, 2003, 34:1043-1047. doi: 10.1053/S0046-8177(03)00409-X [11] Yaziji H, Gown AM. Accuracy and precision in HER-2/neu testing in breast cancer:are we there yet?[J]. Hum Pathol, 2004, 35:143-146. doi: 10.1016/j.humpath.2004.01.002 [12] 曾瑄, 赵大春, 周炜洵, 等.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志, 2005, 34:701-705. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhblx200511001 [13] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol, 2007, 25:118-145. http://www.ncbi.nlm.nih.gov/pubmed/17159189 [14] Dubeau L. The cell of origin of ovarian epithelial tumours[J]. Lancet Oncol, 2008, 9:1191-1197. doi: 10.1016/S1470-2045(08)70308-5 [15] Choi CH, Kim TJ, KimWY, et al. Papillary serous carcinoma in ovaries of normal size:a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma[J]. Gynecol Oncol, 2007, 105:762-768. doi: 10.1016/j.ygyno.2007.02.020 [16] Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma:unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review[J]. Crit Rev Oncol Hematol, 2010, 75:27-42. doi: 10.1016/j.critrevonc.2009.10.003 [17] Bizzi A. Codegoni AM, Landoni F, et al. Steroid receptors in epithelial ovarian carcinoma:relation to clinical parameters and survival[J]. Cancer Res, 1988, 48:6222-6226. http://www.ncbi.nlm.nih.gov/pubmed/3167868 [18] Kommoss F, Pfisterer J, Thome M, et al. Steroid receptors in ovarian carcinoma:immunohistochemical determination may lead to new aspects[J]. Gynecol Oncol, 1992, 47:317-322. doi: 10.1016/0090-8258(92)90133-4 [19] Geisler JP, Wiemann MC, Miller GA, et al. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIC serous cystadenocarcinoma of the ovary[J]. Gynecol Oncol, 1996, 60:424-427. doi: 10.1006/gyno.1996.0067 [20] Lee Y, Park N. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers[J]. Gynecol Oncol, 2009, 112:475-480. doi: 10.1016/j.ygyno.2008.11.031 [21] Vang R, Shih I, Salani R, et al. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data[J]. Am J Surg Pathol, 2008, 32:1667-1674. doi: 10.1097/PAS.0b013e31816fd555 [22] Chen LM, Yamada SD, Fu YS, et al. Molecular similarities between primary peritoneal and primary ovarian carcinomas[J]. Int J Gynecol Cancer, 2003, 13:749-755. doi: 10.1136/ijgc-00009577-200311000-00004 [23] Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas:a multicenter GINECO study of 320 patients[J]. PLoS One, 2007, 2:e1138. doi: 10.1371/journal.pone.0001138 [24] Steffensen KD, Waldstom M, Andersen RF, et al. Protein levels and gene expressions of the epidermal growth factor receptors HER1, HER2, HER3 and HER4 in benign and malignant epithelial ovarian tumours[J]. Int J Oncol, 2008, 33:195-204. http://www.ncbi.nlm.nih.gov/pubmed/18575766